Peptide therapy on TikTok: separating hype from human data

What did @stefanieraya actually say?

After her eighth injection of what she calls "Mazzi" (almost certainly a compounded semaglutide product), @stefanieraya reported feeling leaner in her midsection, mentally clearer, and slightly fatigued. She's dosing at 60 units and planning to bump from three to four injections per week, which is a significant deviation from standard GLP-1 protocols. She also pitched a "cheat sheet" covering 30 peptides as a comment-gated giveaway.

To be direct: she's sharing a personal log of an injectable medication, not a peptide in the strict research sense. Semaglutide is a GLP-1 receptor agonist, a regulated pharmaceutical. The peptide community has absorbed it, but that framing matters for understanding what the actual risks and evidence look like.

Does the science back this up?

On the visceral fat claim, yes, semaglutide has real evidence behind it, but the timeline and mechanism she implies deserve scrutiny. After only eight doses, the subjective feeling of being leaner is more likely a result of reduced appetite, lower caloric intake, and possibly early water weight changes than measurable visceral fat loss.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed a mean 14.9% body weight reduction over 68 weeks at 2.4 mg weekly dosing. Visceral adipose tissue reduction was documented in imaging substudies, but those changes were measured over months, not a few weeks. A 2022 analysis by Lingvay et al. in The Lancet confirmed that body composition improvements, specifically visceral fat, accumulate with sustained treatment and caloric deficit, not as an early acute effect. The "clarity" she describes is plausible. GLP-1 receptors are expressed in the brain, and some participants in semaglutide trials have reported improved cognitive focus, though this is a secondary observation, not a primary endpoint in any major trial.

What did they get wrong (or right)?

The fatigue she mentions is real and documented. It's a common early side effect tied to reduced caloric intake and the medication's gastrointestinal effects. Telling her audience "my body will catch up" is optimistic but not clinically dangerous as a statement.

What's more concerning: she's self-adjusting her dosing frequency from three to four times per week without any clinical rationale. Standard semaglutide protocols involve once-weekly subcutaneous injection with a slow titration schedule precisely to manage GI side effects and avoid dose-dumping issues. Increasing injection frequency on a weekly medication is not how semaglutide pharmacokinetics work. The drug has a half-life of approximately one week (Overgaard et al., 2016, Clinical Pharmacokinetics), meaning more frequent dosing doesn't behave the same way as with short-acting peptides. This is genuinely bad advice embedded in what sounds like a casual update.

She gets credit for being honest about fatigue instead of painting an unrealistically perfect picture. That's more than many creators do.

What should you actually know?

If you're watching this and thinking about semaglutide for visceral fat reduction, the underlying goal is legitimate. Visceral fat is associated with metabolic risk, and GLP-1 receptor agonists have a meaningful evidence base for reducing it. But the framing here skips several things you need to know.

First, "Mazzi" or any compounded semaglutide is not the same product as Ozempic or Wegovy. Compounded versions are not FDA-approved and have variable quality depending on the pharmacy. The FDA issued warnings in 2023 and 2024 about compounded semaglutide products, including reports of dosing errors and contamination. Second, semaglutide is not a peptide in the category of BPC-157 or TB-500. Grouping them conflates a well-studied regulated drug with a much murkier research landscape. Third, her comment-gated "cheat sheet" covering 30 peptides is a red flag. Peptide information packaged as a social media freebie is rarely calibrated to individual health context, and some peptides on those lists have no human clinical trial data at all.

• Work with a licensed provider who can monitor labs and titrate dose appropriately.
• Visceral fat reduction from semaglutide takes months, not eight injections.
• Self-adjusting injection frequency on a once-weekly drug is not supported by the pharmacology.

Bottom line

@stefanieraya's experience sounds genuine, and her honesty about fatigue is refreshing. But the dosing frequency change she's casually planning is pharmacologically unsound, and the visceral fat results she's attributing to eight shots are almost certainly premature. The science on semaglutide for body composition is solid over time. The timeline she's implying is not.